Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459387 | 0.97 | L3MBTL1 (0.64) | ACACBGAAL3MBTL1HRH3CMA1 | |
| SCHEMBL20303832 | 0.95 | L3MBTL1 (0.67) | ACACBGAAL3MBTL1HRH3CMA1 | |
| SCHEMBL11432095 | 0.90 | GAA (0.68) | ACACBGAAL3MBTL1CMA1SMN1; SMN2 | |
| SCHEMBL158547 | 0.88 | GAA (0.55) | ACACBGAAL3MBTL1HRH3CMA1 | |
| SCHEMBL11200681 | 0.86 | L3MBTL1 (0.76) | ACACBL3MBTL1HRH3SMN1; SMN2KMT2A | |
| SCHEMBL16429902 | 0.84 | KMT2A (0.64) | L3MBTL1HRH3SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL1445857 | 0.84 | GAA (0.57) | ACACBGAACMA1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22084085 | 0.84 | L3MBTL1 (0.59) | ACACBGAAL3MBTL1HRH3SMN1; SMN2 | |
| SCHEMBL23747345 | 0.83 | SMN1; SMN2 (0.66) | L3MBTL1SMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL15723517 | 0.82 | SMN1; SMN2 (0.61) | ACACBGAACMA1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0003602-B1 | PYRROLIDINE DERIVATIVES FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-12 | — | — | EP | claimed |
| US-4349562-A | COUNTERACTING CEREBRAL INSUFFICIENCY OR IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1982-09-14 | — | — | US | claimed |
| US-4239770-A | Substituted 2-pyrrolidinones for counteracting cerebral insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1980-12-16 | — | — | US | claimed |
| EP-0003602-A1 | Pyrrolidine derivatives for use as therapeutically active substances and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-08-22 | — | — | EP | claimed |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2025-09-23 | — | — | US | disclosed |
| WO-2025096637-A1 | SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2025-05-08 | — | — | WO | disclosed |
| CN-112334191-B | Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms | 普林特商业服务有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240270752-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2024-08-15 | — | — | US | disclosed |
| CN-117924285-A | Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms | 普林特商业服务有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117567498-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2023-12-19 | — | — | US | disclosed |
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-0003602-B1 | PYRROLIDINE DERIVATIVES FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-12 | — | — | EP | disclosed |
| EP-0002836-B1 | ACYLHYDROCARBYLAMINOALCANECARBOXYLIC ACIDS, THEIR PREPARATION AND THEIR USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-10-27 | — | — | EP | disclosed |
| US-4349562-A | COUNTERACTING CEREBRAL INSUFFICIENCY OR IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1982-09-14 | — | — | US | disclosed |
| US-4243678-A | GASTROINTESTINAL DISORDERS, LIVER DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1981-01-06 | — | — | US | disclosed |
| US-4239770-A | Substituted 2-pyrrolidinones for counteracting cerebral insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1980-12-16 | — | — | US | disclosed |
| EP-0003602-A1 | Pyrrolidine derivatives for use as therapeutically active substances and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-08-22 | — | — | EP | disclosed |
| EP-0003056-A1 | N-substituted omega-aminoalkanoyl-omega-aminoalkanecarboxylic acids, their application and process for their preparation, and medicines containing these compounds | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1979-07-25 | — | — | EP | disclosed |
| EP-0002836-A1 | Acylhydrocarbylaminoalcanecarboxylic acids, their preparation and their use, and pharmaceutical compositions containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | LRRK2, DTYMK, LMTK2 | ACACB 4112/4885GAA 1428/4885L3MBTL1 795/4885 |
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | ACACB 3130/4885GAA 645/4885L3MBTL1 4080/4885 |
| US-20240270752-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | ACACB 3130/4885GAA 645/4885L3MBTL1 4080/4885 |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | ACACB 3130/4885GAA 645/4885L3MBTL1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.